Clinical Study Of PD-1 Inhibitor Combined With Targeted Drugs In The Treatment Of BCLC Stage B/C Liver Cancer

Objective: To investigate the treatment and safety of PD-1 inhibitor combined with molecular targeted drugs in the treatment of advanced hepatocellular carcinoma.Methods: a retrospective study was conducted to study the clinical medical records of patients with hepatocellular carcinoma with BCLC stage B or C in the hepatobiliary pancreatic diagnosis and treatment center of Shiyan Taihe hospital from August 2019 to January 2022.Data collection methods include medical record retrieval system,long-term outpatient data,telephone follow-up,etc.Data collection included gender,age,ECOG-ps score,hepatitis,AFP level,ALT,TB,ALB,tumor diameter,tumor number,child Pugh grade,BCLC stage,etc.All patients finally included in the study were followed up for at least 12 months to compare the efficacy,survival rate,incidence of adverse reactions between the two groups.Results: the short-term efficacy indexes of targeted combined immunotherapy group and targeted treatment group six months after treatment: the number of CR cases were 1(4.3%)and 1(2.2%),the number of PR cases were 16(63.3%)and 15(39.1%),the number of SD cases were 5(20.3%)and 6(15.2%),and the number of PD cases were 4(12.1%)and 16(43.5%)respectively.The ORR of targeted combined immunotherapy group and targeted therapy group were 67.6% and 41.3% respectively,with significant difference(? 2=4.980,P=0.036).The DCR of targeted combined immunotherapy group and targeted therapy group were 87.9% and 56.5% respectively,and the difference was also statistically significant(? 2=6.147,P=0.025).There was no difference in the 3-month survival rate between the two groups.The 6-month survival rates of targeted combined immunotherapy group and targeted treatment group were 71.0% and 59.8% respectively,with significant difference(? 2 = 4.983,P =0.017).The 12-month survival rates of targeted combined immunotherapy group and targeted treatment group were 57.9% and 38.0%,respectively(? 2=5.513,P=0.041)?Conclusion: PD-1 inhibitor combined with molecular targeted drugs can improve the objective response rate and prolong the survival time of patients with advanced hepatocellular carcinoma.The combined treatment strategy has definite curative effect and controllable safety,which brings new hope and dawn for the treatment of patients with advanced hepatocellular carcinoma.